uniQure N.V.

QURE trades with a 16.57% short float—notably elevated for a biotech name—while RSI sits at 68.5, signaling overbought conditions that typically precede pullbacks. The absence of a P/E ratio underscores this is a pre-profitability story where sentiment and pipeline catalysts drive valuations far more than earnings power. The combination of stretched momentum and meaningful short interest creates potential squeeze dynamics, though the shorts may have legitimate concerns about execution risk. At $1.6B market cap and sitting below its 52-week high, this stock appears caught between speculative enthusiasm and fundamental skepticism—a dangerous middle ground where whipsaws tend to punish both sides.